The most encouraging results derive from ALTER 1202, a randomized Chinese phase II study which evaluated the effectiveness of anlotinib (an oral mTKI that targets VEGFR, FGFR, PDGFR, and c-KIT) vs. placebo as third or subsequent line of treatment in 120 patients with SCLC. Here, KIT is linked to small cell lung carcinoma.